.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Progress and Promise: Advancing Treatment in Relapsed/Refractory Multiple Myeloma

On June 13, 2025, a select group of experts in multiple myeloma (MM) participated in an OncLive® scientific interchange and workshop to discuss treatment strategies in relapsed/refractory MM (R/R MM). Moderated by Peter Voorhees, MD, the discussion covered insights on the evolving role of CAR T, emerging therapies that may impact the current treatment landscape, and various treatment strategies with bispecific antibodies in R/R MM.

EP. 1: Progress and Promise: Advancing Treatment in Relapsed/Refractory Multiple Myeloma

July 8th 2025

On June 13, 2025, a select group of experts in multiple myeloma (MM) participated in an OncLive® scientific interchange and workshop to discuss treatment strategies in relapsed/refractory MM (R/R MM). Moderated by Peter Voorhees, MD, the discussion covered insights on the evolving role of CAR T, emerging therapies that may impact the current treatment landscape, and various treatment strategies with bispecific antibodies in R/R MM.